Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Placebo (match to Evobrutinib)Drug: Placebo (match to Teriflunomide)
- Registration Number
- NCT04338022
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Brief Summary
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1124
- Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
- Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
- Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score <= 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
- Participants are neurologically stable for >= 30 days prior to both screening and baseline (Day 1)
- Female participants must be neither pregnant nor breast-feeding or must lack child-bearing potential (as defined by either: post-menopausal or surgically sterile), or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
- Male participants must refrain from donating sperm and/or abstain from intercourse with women of child-bearing potential or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
- Participants have given written informed consent prior to any study-related procedure
- Other protocol defined inclusion criteria could apply.
- Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b).
Participants with secondary progressive MS without evidence of relapse
- Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 at screening and Baseline (Day 1)
- Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV) , intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
- Other protocol defined exclusion criteria could apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Teriflunomide + Evobrutinib matched Placebo: DB Period Teriflunomide - Teriflunomide + Evobrutinib matched Placebo: DB Period Placebo (match to Evobrutinib) - Evobrutinib + Teriflunomide matched Placebo: DB Period Placebo (match to Teriflunomide) - Evobrutinib + Teriflunomide matched Placebo: DB Period Evobrutinib -
- Primary Outcome Measures
Name Time Method DBTP: Annualized Relapse Rate (ARR) Up to 156 weeks The annualized relapse rates up to 156 weeks will be calculated based on qualified relapses. Qualifying relapse is defined as occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than 24 hours, no fever, infection, injury, adverse events, and preceded by a stable or improving neurological state for greater than or equal to (=\>) 30 days).
DBE Period: ARR Up to 96 weeks The annualized relapse rates up to 96 weeks will be calculated based on qualified relapses. Qualifying relapse is defined as occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than 24 hours, no fever, infection, injury, adverse events, and preceded by a stable or improving neurological state for greater than or equal to (=\>) 30 days).
OLE Period: Number of Participants with Adverse Events and Serious Adverse Events (SAE)s Baseline OLE up to 96 weeks
- Secondary Outcome Measures
Name Time Method DBE Period: Time to First Occurrence of 24-Week CDI as measured by EDSS Improvement Up to 96 weeks DBE Period: Change From Baseline in PROMIS MS PF Short Form Score Baseline up to 96 weeks DBE Period: Total Number of New or Enlarging T2 Lesions Assessed on the Last Available MRI Scans Relative to Baseline MRI Scan Up to Week 96 DBE Period: Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs) Baseline up to 96 weeks An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.
DBE Period: Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings Baseline up to 96 weeks Number of participants with clinically significant change from baseline in vital signs, laboratory parameters and electrocardiogram findings will be reported.
DBTP: Time to First Occurrence of 24-Week CDP as measured by EDSS Progression Up to 156 weeks OLE Period: PROMIS Fatigue (MS) 8a Score Change Over Time Baseline OLE up to 96 weeks DBTP: Time to First Occurrence of 12-Week Confirmed Disability Progression (CDP) as measured by Expanded Disability Status Scale (EDSS) Progression Up to 156 weeks DBTP: Time to First Occurrence of 24-Week Confirmed Disability Improvement (CDI) as measured by EDSS Improvement Up to 156 weeks DBTP: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Physical Function (PF) Short Form Score Baseline up to 96 weeks DBTP: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Fatigue Short Form Score Baseline up to 96 weeks DBTP: Total Number of Gadolinium-Enhancing (Gd+) T1 Lesions Assessed by all Available Magnetic Resonance Imaging (MRI) Scans Up to Week 156 DBTP: Total Number of New or Enlarging T2 Lesions Assessed by the Last Available Magnetic Resonance Imaging (MRI) Scan Relative to Baseline MRI Scan Up to Week 156 DBTP: Neurofilament light chain (NfL) Serum Concentration At Week 12 DBTP: Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs) Baseline up to 156 weeks An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.
DBTP: Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings Baseline up to 156 weeks Number of participants with clinically significant change from baseline in vital signs, laboratory parameters and electrocardiogram findings will be reported.
DBTP: Absolute Concentrations of Immunoglobulin (Ig) Levels Baseline up to 156 weeks DBTP: Change From Baseline in Immunoglobulin (Ig) Levels Baseline up to 156 weeks DBE Period: Time to First Occurrence of 12-Week CDP as measured by EDSS Progression Up to 96 weeks DBE Period: Time to First Occurrence of 24-Week CDP as measured by EDSS Progression Up to 96 weeks OLE Period: ARR based on protocol-defined qualified relapses Baseline OLE up to 96 weeks OLE Period: Symbol Digital Modalities Test Over time Baseline OLE up to 96 weeks OLE Period: PROMISnq PF (MS) 15a score change over time Baseline OLE up to 96 weeks OLE Period: Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Electrocardiogram (ECG) and Laboratory Findings Baseline OLE up to 96 weeks OLE: Change from Baseline in T2 lesion Volume Over Time Baseline OLE up to 96 weeks DBE Period: Change From Baseline in PROMIS MS Fatigue Short Form Score Baseline up to 96 weeks DBE Period: Total Number of Gd+ T1 Lesions Assessed by all Available MRI Scans Up to Week 96 OLE Period: Time to first occurrence of 24-week CDP as measured by EDSS Baseline OLE up to 96 weeks DBE Period: Change From Baseline in Immunoglobulin (Ig) Levels Baseline up to 96 weeks OLE Period: Time to first occurrence of 24-week CDI as measured by EDSS Baseline OLE up to 96 weeks DBE Period: Absolute Concentrations of Immunoglobulin (Ig) Levels Baseline up to 96 weeks OLE: Total Number of New or Enlarging T2 Lesions Assessed on the Last Available Magnetic Resonance Imaging (MRI) Scans Baseline OLE up to 96 weeks
Trial Locations
- Locations (279)
Research Site 612
🇺🇸Farmington Hills, Michigan, United States
Research Site 151
🇦🇹Innsbruck, Austria
Research Site 153
🇦🇹Vienna, Austria
Research Site 250
🇬🇪Tbilisi, Georgia
Research Site 263
🇩🇪Frankfurt, Germany
Research Site 272
🇩🇪Mannheim, Germany
Research Site 262
🇩🇪Muenchen, Germany
Research Site 282
🇭🇺Budapest, Hungary
Research Site 320
🇮🇹Messina, Italy
Research Site 317
🇮🇹Napoli, Italy
Research Site 312
🇮🇹Salerno, Italy
Research Site 432
🇺🇦Chernivtsi, Ukraine
Research Site 634
🇺🇸Stamford, Connecticut, United States
Research Site 616
🇺🇸Boca Raton, Florida, United States
Research Site 476
🇧🇪Roeselare, Belgium
Research Site 620
🇺🇸Patchogue, New York, United States
Research Site 647
🇺🇸Willow Grove, Pennsylvania, United States
Research Site 174
🇧🇬Pleven, Bulgaria
Research Site 574
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Research Site 177
🇧🇬Plovdiv, Bulgaria
Research Site 663
🇺🇸Akron, Ohio, United States
Research Site 667
🇺🇸Audubon, New Jersey, United States
Research Site 654
🇺🇸Virginia Beach, Virginia, United States
Research Site 129
🇨🇦Montreal, Canada
Research Site 676
🇺🇸Layton, Utah, United States
Reasearch Site 175
🇧🇬Plovdiv, Bulgaria
Research Site 562
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Research Site 179
🇧🇬Sofia, Bulgaria
Research Site 561
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Research Site 571
🇦🇷Salta, Argentina
Research Site 577
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Research Site 178
🇧🇬Sofia, Bulgaria
Research Site 673
🇺🇸Alexandria, Virginia, United States
Research Site 124
🇨🇦Toronto, Canada
Research Site 171
🇧🇬Pleven, Bulgaria
Research Site 567
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Research Site 172
🇧🇬Sofia, Bulgaria
Research Site 125
🇨🇦Levis, Canada
Research Site 579
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Research Site 101
🇦🇺Liverpool, Australia
Research Site 103
🇦🇺St Leonards, Australia
Research Site 193
🇭🇷Osijek, Croatia
Research Site 197
🇭🇷Rijeka, Croatia
Research Site 473
🇧🇪Kortrijk, Belgium
Research Site 173
🇧🇬Sofia, Bulgaria
Research Site 472
🇧🇪Liège, Belgium
Research Site 511
🇫🇷Nantes cedex 1, France
Research Site 180
🇧🇬Sofia, Bulgaria
Research Site 211
🇨🇿Jihlava, Czechia
Research Site 218
🇨🇿Brno, Czechia
Research Site 232
🇪🇪Tartu, Estonia
Research Site 247
🇬🇪Tbilisi, Georgia
Research Site 504
🇫🇷Lille cedex, France
Research Site 503
🇫🇷Toulouse cedex 9, France
Research Site 224
🇨🇿Praha 5, Czechia
Research Site 176
🇧🇬Sofia, Bulgaria
Research Site 212
🇨🇿Brno, Czechia
Research Site 192
🇭🇷Zagreb, Croatia
Research Site 502
🇫🇷Grenoble cedex 09, France
Reserach Site 505
🇫🇷Montpellier, France
Research Site 219
🇨🇿Hradec Kralove, Czechia
Research Site 216
🇨🇿Plzen-Bory, Czechia
Research Site 220
🇨🇿Praha 2, Czechia
Research Site 597
🇨🇴Barranquilla, Colombia
Research Site 491
🇫🇮Turku, Finland
Research Site 249
🇬🇪Tbilisi, Georgia
Research Site 195
🇭🇷Varazdin, Croatia
Research Site 194
🇭🇷Zagreb, Croatia
Research Site 264
🇩🇪Bochum, Germany
Research Site 217
🇨🇿Praha 10, Czechia
Research Site 231
🇪🇪Tallinn, Estonia
Research Site 246
🇬🇪Tbilisi, Georgia
Research Site 342
🇵🇱Warszawa, Poland
Research Site 383
🇷🇸Belgrade, Serbia
Research Site 363
🇷🇺Krasnoyarsk, Russian Federation
Research Site 355
🇷🇺Kaluga, Russian Federation
Research Site 351
🇷🇺Ufa, Russian Federation
Research Site 401
🇪🇸Lleida, Spain
Research Site 284
🇭🇺Pecs, Hungary
Research Site 291
🇭🇺Vac, Hungary
Research Site 359
🇷🇺Moscow, Russian Federation
Research Site 311
🇮🇹Reggio Calabria, Italy
Research Site 385
🇷🇸Belgrade, Serbia
Research Site 362
🇷🇺Pyatigorsk, Russian Federation
Research Site 335
🇵🇱Gdansk, Poland
Research Site 406
🇪🇸Barcelona, Spain
Research Site 331
🇵🇱Oswiecim, Poland
Research Site 425
🇺🇦Kharkiv, Ukraine
Research Site 436
🇺🇦Kharkiv, Ukraine
Research Site 437
🇺🇦Kharkiv, Ukraine
Research Site 382
🇷🇸Belgrade, Serbia
Research Site 405
🇪🇸Cadiz, Spain
Research Site 532
🇳🇱Sittard-Geleen, Netherlands
Research Site 407
🇪🇸Barcelona, Spain
Research Site 411
🇪🇸Pozuelo de Alarcon, Spain
Research Site 365
🇷🇺Barnaul, Russian Federation
Research Site 340
🇵🇱Knurow, Poland
Research Site 337
🇵🇱Lublin, Poland
Research Site 711
🇨🇳Taichung, Taiwan
Research Site 336
🇵🇱Katowice, Poland
Research Site 316
🇮🇹Napoli, Italy
Research Site 409
🇪🇸Madrid, Spain
Research Site 464
🇰🇷Seoul, Korea, Republic of
Research Site 402
🇪🇸San Sebastian, Spain
Research Site 354
🇷🇺Kirov, Russian Federation
Research Site 367
🇷🇺Perm, Russian Federation
Research Site 339
🇵🇱Lodz, Poland
Research Site 341
🇵🇱Warszawa, Poland
Research Site 389
🇷🇸Kragujevac, Serbia
Research Site 353
🇷🇺Moscow, Russian Federation
Research Site 404
🇪🇸Sevilla, Spain
Research Site 338
🇵🇱Rzeszów, Poland
Research Site 424
🇺🇦Odesa, Ukraine
Research Site 356
🇷🇺St.Petersburg, Russian Federation
Research site 713
🇨🇳Kaohsiung, Taiwan
Research Site 544
🇬🇧Exeter, United Kingdom
Research Site 426
🇺🇦Lviv, Ukraine
Research Site 547
🇬🇧Swansea, United Kingdom
Research Site 633
🇺🇸Boston, Massachusetts, United States
Research Site 624
🇺🇸Indianapolis, Indiana, United States
Research Site 631
🇺🇸Houston, Texas, United States
Research Site 623
🇺🇸Baltimore, Maryland, United States
Research Site 672
🇺🇸San Diego, California, United States
Research Site 613
🇺🇸Detroit, Michigan, United States
Research Site 637
🇺🇸Nashville, Tennessee, United States
Research Site 126
🇨🇦Greenfield Park, Canada
Research Site 128
🇨🇦Moncton, Canada
Research Site 506
🇫🇷Nice Cedex 1, France
Research Site 368
🇷🇺Ekaterinburg, Russian Federation
Research Site 358
🇷🇺Kazan, Russian Federation
Research Site 369
🇷🇺Saint-Petersburg, Russian Federation
Research Site 360
🇷🇺Saratov, Russian Federation
Research Site 361
🇷🇺Smolensk, Russian Federation
Research Site 357
🇷🇺Ulyanovsk, Russian Federation
Research Site 366
🇷🇺Yaroslavl, Russian Federation
Research Site 269
🇩🇪Ulm, Germany
Research Site 564
🇦🇷Cordoba, Argentina
Research Site 563
🇦🇷San Miguel de Tucuman, Argentina
Research Site 568
🇦🇷Godoy Cruz, Argentina
Research Site 569
🇦🇷Rosario, Argentina
Research Site 427
🇺🇦Sumy, Ukraine
Research Site 629
🇺🇸Mobile, Alabama, United States
Research Site 677
🇺🇸Phoenix, Arizona, United States
Research Site 614
🇺🇸Phoenix, Arizona, United States
Research Site 642
🇺🇸Long Beach, California, United States
Research Site 644
🇺🇸Pasadena, California, United States
Research Site 656
🇺🇸Washington, District of Columbia, United States
Research site 645
🇺🇸Saint Petersburg, Florida, United States
Research Site 628
🇺🇸Rolling Meadows, Illinois, United States
Research Site 675
🇺🇸Peoria, Illinois, United States
Research Site 290
🇭🇺Budapest, Hungary
Research Site 635
🇺🇸Lawrence, Massachusetts, United States
Research Site 636
🇺🇸Worcester, Massachusetts, United States
Research Site 639
🇺🇸Foxboro, Massachusetts, United States
Research Site 668
🇺🇸Omaha, Nebraska, United States
Research Site 307
🇮🇱Petah Tikva, Israel
Research Site 641
🇺🇸Oklahoma City, Oklahoma, United States
Research Site 615
🇺🇸Springfield, Oregon, United States
Research Site 627
🇺🇸Nashville, Tennessee, United States
Research Site 650
🇺🇸Lubbock, Texas, United States
Research Site 651
🇺🇸Milwaukee, Wisconsin, United States
Research Site 566
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Research Site 576
🇦🇷Guaymallen, Argentina
Research Site 565
🇦🇷Rosario, Argentina
Research Site 572
🇦🇷San Juan, Argentina
Research Site 109
🇦🇺Hobart, Australia
Research Site 104
🇦🇺Auchenflower, Australia
Research Site 154
🇦🇹Salzburg, Austria
Research Site 107
🇦🇺Concord, Australia
Research Site 102
🇦🇺New Lambton Heights, Australia
Research Site 474
🇧🇪Bruxelles, Belgium
Research Site 475
🇧🇪Bruxelles, Belgium
Research Site 471
🇧🇪La Louvière, Belgium
Research Site 466
🇰🇷Seoul, Korea, Republic of
Research Site 478
🇧🇪Overpelt, Belgium
Research Site 222
🇨🇿Hradec Kralove, Czechia
Research Site 223
🇨🇿Ostrava, Czechia
Research Site 215
🇨🇿Pardubice, Czechia
Research Site 456
🇮🇳Nashik, India
Research Site 510
🇫🇷Bron cedex, France
Research Site 508
🇫🇷Lille, France
Research Site 507
🇫🇷Rennes cedex 09, France
Research Site 501
🇫🇷Rouen Cedex, France
Research Site 509
🇫🇷Caen cedex 9, France
Research Site 213
🇨🇿Praha 4 - Krc, Czechia
Research Site 244
🇬🇪Tbilisi, Georgia
Research Site 241
🇬🇪Tbilisi, Georgia
Research Site 242
🇬🇪Tbilisi, Georgia
Research Site 243
🇬🇪Tbilisi, Georgia
Research Site 245
🇬🇪Tbilisi, Georgia
Research Site 248
🇬🇪Tbilisi, Georgia
Research Site 265
🇩🇪Bamberg, Germany
Research Site 267
🇩🇪Bayreuth, Germany
Research Site 271
🇩🇪Berlin, Germany
Research Site 270
🇩🇪Erbach, Germany
Research Site 274
🇩🇪Bonn, Germany
Research Site 268
🇩🇪Essen, Germany
Research Site 275
🇩🇪Hannover, Germany
Research Site 266
🇩🇪Muenster, Germany
Research Site 273
🇩🇪Siegen, Germany
Research Site 261
🇩🇪Potsdam, Germany
Research Site 700
🇭🇰Hong Kong, Hong Kong
Research Site 704
🇭🇰Hongkong, Hong Kong
Research Site 285
🇭🇺Budapest, Hungary
Research Site 701
🇭🇰Shatin, Hong Kong
Research Site 286
🇭🇺Budapest, Hungary
Research Site 288
🇭🇺Budapest, Hungary
Research Site 281
🇭🇺Kistarcsa, Hungary
Research Site 457
🇮🇳Hyderabad, India
Research Site 289
🇭🇺Tatabanya, Hungary
Research Site 451
🇮🇳New Delhi, India
Research Site 303
🇮🇱Ashkelon, Israel
Research Site 319
🇮🇹Bologna, Italy
Research Site 304
🇮🇱Safed, Israel
Research Site 308
🇮🇱Ramat Gan, Israel
Research Site 301
🇮🇱Rechovot, Israel
Research Site 321
🇮🇹Chieti, Italy
Research Site 322
🇮🇹Genova, Italy
Research Site 315
🇮🇹Milano, Italy
Research Site 314
🇮🇹Montichiari, Italy
Research Site 318
🇮🇹Roma, Italy
Research Site 313
🇮🇹Verona, Italy
Research Site 462
🇰🇷Goyang-si, Korea, Republic of
Research Site 467
🇰🇷Seoul, Korea, Republic of
Research Site 534
🇳🇱Hoorn, Netherlands
Research Site 531
🇳🇱Nieuwegein, Netherlands
Research Site 535
🇳🇱Rotterdam, Netherlands
Research Site 133
🇲🇽Aguascalientes, Mexico
Research Site 134
🇲🇽Culiacan, Mexico
Research Site 332
🇵🇱Bydgoszcz, Poland
Research Site 403
🇪🇸Madrid, Spain
Research Site 408
🇪🇸Madrid, Spain
Research Site 410
🇪🇸Salt, Spain
Research Site 429
🇺🇦Kharkiv, Ukraine
Research site 715
🇨🇳Taipei, Taiwan
Research Site 430
🇺🇦Kharkiv, Ukraine
Research Site 435
🇺🇦Kharkiv, Ukraine
Research Site 438
🇺🇦Kyiv, Ukraine
Research Site 423
🇺🇦Poltava, Ukraine
Research Site 422
🇺🇦Kropyvnytskyi, Ukraine
Research Site 421
🇺🇦Zaporizhzhia, Ukraine
Research Site 552
🇬🇧Newcastle, United Kingdom
Research Site 625
🇺🇸Maitland, Florida, United States
Research Site 617
🇺🇸Miami, Florida, United States
Research Site 621
🇺🇸Elk Grove Village, Illinois, United States
Research Site 649
🇺🇸Northbrook, Illinois, United States
Research Site 652
🇺🇸Tallahassee, Florida, United States
Research Site 643
🇺🇸Ormond Beach, Florida, United States
Research Site 638
🇺🇸Saint Louis, Missouri, United States
Research Site 619
🇺🇸Round Rock, Texas, United States
Research Site 626
🇺🇸Las Vegas, Nevada, United States
Research Site 632
🇺🇸Kansas City, Kansas, United States
Research Site 352
🇷🇺Nizhniy Novgorod, Russian Federation
Research Site 461
🇰🇷Seoul, Korea, Republic of
Research Site 653
🇺🇸New Orleans, Louisiana, United States
Research Site 611
🇺🇸Oklahoma City, Oklahoma, United States
Research Site 664
🇺🇸Saint Louis, Missouri, United States
Research Site 662
🇺🇸Dallas, Texas, United States
Research Site 630
🇺🇸Toledo, Ohio, United States
Research Site 305
🇮🇱Jerusalem, Israel
Research Site 648
🇺🇸Knoxville, Tennessee, United States
Research Site 463
🇰🇷Seoul, Korea, Republic of
Research Site 370
🇷🇺Tomsk, Russian Federation
Research Site 549
🇬🇧Glasgow, United Kingdom
Research Site 465
🇰🇷Seoul, Korea, Republic of
Research Site 156
🇦🇹Linz, Austria
Research Site 592
🇨🇴Medellin, Colombia
Research Site 388
🇷🇸Novi Sad, Serbia
Research site 714
🇨🇳Taipei, Taiwan
Research Site 163
🇧🇦Mostar, Bosnia and Herzegovina
Research Site 162
🇧🇦Sarajevo, Bosnia and Herzegovina
Research Site 600
🇨🇴Medellin, Colombia
Research Site 381
🇷🇸Valjevo, Serbia
Research Site 161
🇧🇦Bihac, Bosnia and Herzegovina
Research Site 591
🇨🇴Barranquilla, Colombia
Research Site 384
🇷🇸Uzice, Serbia
Research Site 390
🇷🇸Nis, Serbia
Research Site 431
🇺🇦Vinnytsia, Ukraine
Research Site 428
🇺🇦Zaporizhzhia, Ukraine